Low-density lipoprotein cholesterol response to statins according to comorbidities and co-medications: A

Giulia Corn1, Marie Lund2, Niklas W Andersson3

  • 1Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.; Danish Cancer Institute, Statistics and Data Analysis, Copenhagen, Denmark.

PubMed

Insights

Statin therapy response varies, but most conditions and medications have little effect. Metformin use significantly enhances LDL-C reduction, potentially allowing for lower statin doses in patients taking this drug.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Pharmacy

Background:

  • Statin therapy effectiveness in lowering low-density lipoprotein cholesterol (LDL-C) shows significant individual variability.
  • This variability may be influenced by co-morbidities and co-medications, impacting treatment strategies.
  • Investigating these factors is crucial for optimizing statin therapy in diverse patient populations.

Purpose of the Study:

  • To determine if common co-morbidities and co-medications significantly impact individual patient responses to statin therapy.
  • To identify specific patient subgroups that may benefit from adjusted statin regimens based on their health status and concomitant drug use.

Main Methods:

  • A Danish register-based cohort study of 89,006 patients initiating simvastatin or atorvastatin between 2008-2018.
  • LDL-C reduction was calculated as percentage reduction difference (PRD) from pre-statin to on-statin levels.
  • Linear regression analyzed PRD across 175 comorbidities and 99 co-medications, assessing statistical and clinical significance (PRD ≥ 5%).

Main Results:

  • Concomitant use of oral blood-glucose lowering drugs, primarily metformin, was linked to a clinically significant and statistically important enhanced statin response (PRD 5.18%).
  • No other comorbidity or co-medication met the criteria for a clinically important effect on statin response.
  • Collectively, comorbidities and co-medications explained only 1.7% of the total population variance in statin response.

Conclusions:

  • Most studied comorbidities and co-medications do not clinically impact statin response, suggesting general treatment regimens are appropriate.
  • Metformin use is associated with significantly improved LDL-C response to statins.
  • This finding suggests potential for using lower statin doses in patients concurrently treated with metformin.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
652
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
155
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
539
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
252
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
729
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K